儿童横纹肌肉瘤的回顾性分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (658 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical characteristics, the comprehensive treatment, curative effect and prognosis of rhabdomyosarcoma.Methods A retrospective analysis was performed on 20 children with rhabdomyosarcoma who visited China People’s Armed Police Hospital from January 31, 2003 to December 31, 2014. The clinical characteristics, comprehensive treatment efficacy and prognosis of these cases were analyzed.Results All the 20 cases were followed up. The median follow-up time was 38 months; among the 20 cases, male: female 2.3∶1, and the median age was 4.25years old. All the children were with rhabdomyosarcoma confirmed by pathological biopsy. According to The United States Rhabdomyosarcoma Study Group (IRS) staging system, stage I 0 cases stageⅡ 6 cases, stage Ⅲ 9 cases and Ⅳ 5 cases; according to World Health Organization (WHO) classification, 17 cases of embryonic type, two cases of alveolar type and 1 case of polymorphous type; 0 case in low-risk group, 15 cases in the median risk group and 5 cases in high risk group. 18 cases original sites were head and neck, 1 case in limbs and 1 case in testies. Treatment consisted of Shanghai Children’s Medical Center RMS 2002 program combined with the United States (IRS) program development program. Seven cases underwent surgery plus chemotherapy and 13 patients underwent combined standard treatment (surgery, chemotherapy and radiotherapy).The efficacy rates: CR12 cases, PR2 cases, PD6 cases, the CR rate was 60%. 5 cases of high-risk all died, 3 patients’ who underwent standard treatment average follow-up time was 39.3 months, and the other two cases’ average follow-up time was 14.4 months.Almost all 13 cases had relapse at 1 year follow-up, among the 13 cases, seven patients received surgery combined with chemotherapy.Conclusions Embryonal rhabdomyosarcoma is the common pathological type. Clinical manifestations lack specificity.The comprehensive standard treatment method(surgery, chemotherapy, radiotherapy)has a certain role in improving the prognosis of rhabdomyosarcoma.

Key words： rhabdomyosarcoma clinical features comprehensive treatment prognostic

Received: 05 March 2016

ZTFLH:

R730

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Ping
	SUN Yanfeng
	YUAN Hailian
	MIAO Lixia
	LI Yanshan
	and LIU Qiuling

Cite this article:

LI Ping,SUN Yanfeng,YUAN Hailian等. Clinical study of 20 cases of children with rhabdomyosarcoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(7): 698-701.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I7/698

[1]	Fletcher C, Bridge J A. Pancras C W, et al. World Health Organization classification of tumours of soft tissue and bone[M], Lyon: IARC press,2013: 130-131.
[2]	Vickie Y J, Christopher D M. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition[J]. Pathology, 2014, 46(2): 95-104.
[3]	胡亚美,江载芳. 褚福棠实用儿科学[M]. 8版. 北京: 人民卫生出版社,2002: 2241-2244.
[4]	Stiller C A, Parkin D M. International variations in the incidence of childhood soft-tissue sarcomas [J]. Paediatr Perinat Epidemiol, 1994, 81(1): 107-119.
[5]	Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. JNCI, 2000, 92(3): 205-216.
[6]	Trotti A, Colevas A D, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment [J]. Semin Radiat Oncol, 2003, 13(3): 176-181.
[7]	于潇菡,侯世科. 眼眶横纹肌肉瘤诊断的研究进展[J]. 医学研究杂志,2008,37(1): 91-93.
[8]	赵敏,冯晨,王建文,等. 儿童横纹肌肉瘤23例临床分析[J]. 中国当代儿科杂志,2011,13(8): 657-660.
[9]	Rodeberg D, Paidas C. Childhood rhabdomyosarcoma [J]. Swmin Pediatr Surg, 2006, 15(1): 57-62.
[10]	汤静燕,潘慈,徐敏,等. 儿童横纹肌肉瘤Rs-99诊断治疗方案远期临床随访报告[J]. 中华医学杂志,2009,89(2):121-123.
[11]	Gouglet A, Perez J, Pissaloux D, et al. miRNA profiling:how to bypass the current difficulties in the diagnosis and treatment of sarcomas[EB/OL].(2011-02-22).[2013-06-12]. http://dx.doi.org/10.1155/2011/460650.
[12]	Janos S, Renae S, Robert W, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX‐FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family[J]. Cancer, 2010, 49(3): 224-236.
[13]	徐莹,唐锁勤,王建文,等. 13例小儿横纹肌肉瘤疗效分析[J]. 中国当代儿科杂志,2008,10(2): 163-166.
[14]	李璋林,闫杰,张广超.儿童横纹肌肉瘤术前治疗的探讨[J]. 中国肿瘤临床,2002,29(6): 407-409.
[15]	Schmidt W G, Lefterova P, Mehta B A, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.[J]. Exp Hematol, 1993, 21(13): 1673-1679.
[16]	Shi M, Zhang B, Tang Z R, et al. Autologus cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma [J]. World J Gastroenterol, 2004, 10(8): 1146-1151.
[17]	Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma [J]. Biol Blood Marrow Transplant, 2005, 11(3):181-187.